TIL therapy uses a patient's immune cells to target cancer, offering a novel treatment for advanced melanoma after anti-PD-1/PD-L1 therapy failure. The FDA approved Amtagvi (lifileucel) in 2024 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback